ELLA

What it isA selective progesterone-receptor modulator taken as single-dose emergency contraception effective up to five days after intercourse.
Why this oneIt outperforms levonorgestrel in the fourth and fifth days and in higher-BMI patients because it still delays ovulation after the LH surge begins.
What limits itCYP3A4 inducers reduce efficacy; progestin-containing contraception started immediately afterward can blunt its effect, so delay restarting it.
Animated chart of estimated U.S. prescriptions per year, Hormonal contraceptives (1960–2026). Ulipristal acetate enters in 2010 (estimated).
Principal riskEctopic pregnancy if it fails; CYP3A4 inducers reduce efficacy
Legacy pregnancy categoryX
Defining liabilityOvulation/contraception interactions and altered menstrual timing
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Emergency contraception (after unprotected intercourse or contraceptive failure) | Females of reproductive potential | One 30 mg tablet PO as soon as possible within 120 h (5 days) | Single dose | 30 mg single dose |
Renal Undefined
Hepatic Undefined
For occasional use; repeat use within the same cycle not recommended
Available strengths
Pregnancy Contraindicated in existing or suspected pregnancy; not indicated for pregnancy termination
Lactation Present in human milk in small amounts (~1% of maternal dose over 5 days)
| Strength | #/mo | generic $/unit | brand $/unit | CostPlus | |
|---|---|---|---|---|---|
| 30 mg | tab | per unit | — | $37.10/ea | not offered |
Open Ulipristal acetate in the interactive console ↗